I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients

Blood Cancer J. 2022 Sep 23;12(9):138. doi: 10.1038/s41408-022-00733-2.

Authors

Affiliations

¹ Department of Medicine, Hackensack Meridian School of Medicine, Hackensack University Medical Center, Hackensack, NJ, USA. sarvarinder.gill@hmhn.org.
² Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack Meridian School of Medicine, Hackensack University Medical Center, Hackensack, NJ, USA.
³ Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC, USA.

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Dexamethasone / therapeutic use
Humans
Multiple Myeloma* / drug therapy
Rubiaceae*

Substances

Dexamethasone